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Introduction
Corticosteroids administered during pregnancy or maternal
Cushing’s syndrome can cause suppression of fetal adrenal
glands (1,2,3,4,5,6,7). Maternal use of corticosteroids is 
needed in case of fetal congenital adrenal hyperplasia, as well
as in maternal diseases such as idiopathic thrombocytopenic
purpura (ITP), Crohn’s disease, systemic lupus erythematosus,
Addison’s disease and rheumatological problems (3,8,9). 
Short-term corticosteroid treatment is given in case of preterm
labor to enhance fetal lung maturation (8). When using 
corticosteroids during pregnancy, the choice of preparation
type and dose is of utmost importance - steroids crossing the
placenta freely should be given if the target is fetus,  while
those  passing across the placenta should be used in smaller
amount if maternal disorders are being treated (1).
In this article, adrenal suppression pattern in a newborn
exposed to long-term maternal methylprednisolone therapy
were presented with special emphasis on short term follow up
of such infants.  
Case
A 20-minute-old newborn, whose mother used 64 mg
methylprednisolone per day during her pregnancy due to ITP,
was hospitalized for follow-up. Pregnancy duration was 39
weeks. The neonate was 2680 grams (3-10th percentile) at
birth with head circumference of 36 cm (75-90th percentile) and
height of 50 cm (25-30th percentile). Whole blood examination
showed hemoglobin level of 19.1 g/dL, leukocyte count of 10
530/mm3, and platelet count of 10 000/mm3. Biochemistry 
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profile revealed the following: blood glucose 29 mg/dL, 
sodium level 138 mEq/L, potassium 4.5 mEq/L, ALT 18 U/L,
AST 62 U/L, calcium 9.5 mg/dL, phosphorus 4.8 mg/L, alkaline
phosphatase 100 U/L, parathormone 13.91 pg/mL. On adrenal
ultrasonographic examination, the adrenal glands were small
measuring 10x2 mm in size for the right and 12x2 mm for the
left one. Since the patient was thrombocytopenic, 0.8 g/kg
IVIG infusion was given and repeated platelet count was 30
000 mm3. On the third day of follow-up, sodium level became
123 mEq/L, potassium 3.9 mEq/L, and urinary sodium level
was 26 mEq/L. On the fourth day, cortisol level was 16.22
μg/dL, ACTH was 44.4 pg/mL, 17-OH progesterone was 2.58
ng/mL. On the 10th day, rechecking the adrenal functions, 
cortisol level was found to be 0.194 μg/dL and ACTH 20.9
pg/mL. After administration of 1 μg of ACTH i.v. (low-dose
ACTH test), the cortisol level increased to 9.69 μg/dL at 30
minute. Then, the patient was given 3 mg/m2/day p.o. 
methylprednisolone as physiological replacement. The result
of low-dose ACTH test on the 40th day postpartum was as 
follows: basal cortisol level of 4.29 μg/dL and 30th minute 
cortisol level of 11.29 μg/dL. Therefore, methylprednisolone
therapy was continued  and stopped by slowly tapering at the
end of the 3rd month (Table 1). Low-dose ACTH test was
repeated in the 4th posnatal month  and the results were as
follows: basal cortisol 4.75 μg/dL, ACTH 19.5 pg/dL. After 30
minutes, cortisol level was 19.9 μg/dL. Hormone tests and
their results are summarized in Table 1. These results showed
that the patient was relived from adrenal suppression.  
Discussion 
Corticosteroids are given during pregnancy if needed in
maternal diseases or other pregnancy-related problems as
well as to treat certain fetal diseases; in the latter cases, 
corticosteroids capable of crossing the placenta are 
administered to the mother (5,6,7,8,9).
As side effects to the mother, steroids used during 
pregnancy can cause weight gain, dyslipidemia, 
hypertension, cushingoid appearance, acne, hypertrichosis,
psychological problems (8). Corticosteroids are metabolized
in the placenta by the help of the enzyme 11-β-hydroxylase
steroid dehydrogenase-2 (10). Cortisol, a physiologic
steroid, is metabolized to cortisone. Similarly, synthetic 
glucocorticosteroids are metabolized to inactive 
metabolites in the placenta. Prednisolone-related drugs are
mostly degraded to inactive forms by the placental
enzymes and, approximately 10% of the total amount will
ultimately reach the fetus and among this whole, about
33% of betamethasone and 50% of dexamethasone will
enter the fetal circulation (11,12).  Besides this, when taken
in high doses and for long period of time, prednisolone and 
methylprednisolone themselves can saturate the placental
enzymes and, as a result, large amount of corticosteroids
can cross the placental barrier causing significant 
suppression of the fetal glands, as observed in our case (5).
Fetal adrenal suppression develops approximately within 14
days after maternal steroid use, therefore, the neonate may
be born with ACTH suppression (5). Adrenal gland 
insufficiency becomes prominent on postnatal day 
3 - the neonate develops hyponatremia, hypoglycemia and
hypotension. Since there is central adrenal insufficiency
due to long-term steroid effect, potassium level is within
normal limits, or even low. It is well known that 
long-term steroid use can cause low birth weight, as in 
our case (12). 
In our patient, high-dose methylprednisolone saturated
the placental enzymes, the steroids crossed the placenta
more significantly and in higher amounts, thus, causing fetal
adrenal suppression.  On the fourth day, cortisol level was
within normal ranges, but we consider that there might be an 
interference between crossed maternal steroids, their 
metabolites and fetal cortisol. Since on the 10th day ACTH
and cortisol levels were found to be suppressed, this shows
the importance of measuring cortisol and ACTH levels during
the second week. 
Thus, steroids crossing the placenta in small amount should
be preferred during pregnancy in case of maternal disorders
necessitating steroid use. The newborns should be followed
postnatally. On postnatal day 4, basal cortisol and ACTH levels
should be measured, and if needed, adrenal reserves should be
checked by conducting low-dose ACTH test. Although there are
many references for threshold of cortisol response to low-dose
ACTH test, for term newborns, levels of 20 μg/dL and above
should be accepted as normal response (13). 
Table 1. Hormone levels and treatment of the patient during follow-up
Basal Response to
low-dose ACTH test
Time Cortisol (μg/dL) ACTH (pg/mL) Cortisol (μg/dL) Treatment
4th day 16.22 44.4 - None
10thday 0.194 20.9 9.69 3mg/m2/day methylprednisolone
40th day 4.29 - 11.29 Continued methylprednisolone therapy 
until the end of the 3rd month
4th month 4.75 19.5 19.9 None162
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For patients with adrenal insufficiency, physiological
replacement should be started. Moreover, in case of stressful
conditions, the dose of steroid should be increased 2-3 times,
because it has been shown that antenatal steroids can change
the response to neonatal stress (14). Low-dose ACTH test
should be repeated at specified intervals and, as soon as 
adrenal response returns to normal, replacement therapy
should be slowly tapered and stopped. 
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